Monitor for development of EGFR T790M drug-resistant mutation in patients administered tyrosine kinase inhibitor (TKI) therapy for EGFR-mutant non-small cell lung cancer. Monitor response to therapy and disease progression in patients treated with EGFR T790M-specific TKIs.
Polymerase Chain Reaction
New York DOH Approval Status
Whole blood in two 10 mL Cell-Free DNA (cfDNA) BCT Tubes (ARUP Supply #52358) available online through eSupply or contacting ARUP Client Services at (800) 522-2787. Also acceptable: CSF collected in a sterile container.
Whole Blood: Transport 20 mL whole blood. (Min: 16 mL)
CSF: Transport 4 mL CSF. (Min: 4 mL)
FFPE tissue. Whole Blood collected in non-cfDNA BCT tubes.
Whole Blood: Ambient: 5 days; Refrigerated: 5 days; Frozen: Unacceptable
CSF: Ambient: Unacceptable; Refrigerated: 5 days; Frozen: Unacceptable
Refer to report.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|2012869||EGFR T790M Result||55769-4|